Investors & Media

What’s new.

Press releases

Press releases.

April 18th 2024

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76

April 17th 2024

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

March 5th 2024

Immutep Announces First Clinical Data from 90mg Dosing of Efti

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

April 19th 2024

Ladenburg Thalmann - Autoimmune Program is Advancing into Clinic; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 18th 2024

Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 4th 2024

Bell Potter - Thoughts Ahead of TACTI-003 Readout; Maintain Buy, A$0.65 tgt (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

more